Company Quick10K Filing
Cooper Companies
Price294.25 EPS9
Shares50 P/E32
MCap14,712 P/FCF21
Net Debt1,173 EBIT546
TEV15,886 TEV/EBIT29
TTM 2019-10-31, in MM, except price, ratios
10-Q 2020-04-30 Filed 2020-06-05
10-Q 2020-01-31 Filed 2020-03-06
10-K 2019-10-31 Filed 2019-12-20
10-Q 2019-07-31 Filed 2019-08-30
10-Q 2019-04-30 Filed 2019-05-31
10-Q 2019-01-31 Filed 2019-03-06
10-K 2018-10-31 Filed 2018-12-21
10-Q 2018-07-31 Filed 2018-08-31
10-Q 2018-04-30 Filed 2018-06-08
10-Q 2018-01-31 Filed 2018-03-09
10-K 2017-10-31 Filed 2017-12-22
10-Q 2017-07-31 Filed 2017-09-01
10-Q 2017-04-30 Filed 2017-06-02
10-Q 2017-01-31 Filed 2017-03-03
10-K 2016-10-31 Filed 2016-12-22
10-Q 2016-07-31 Filed 2016-09-02
10-Q 2016-04-30 Filed 2016-06-03
10-Q 2016-01-31 Filed 2016-03-04
10-K 2015-10-31 Filed 2015-12-18
10-Q 2015-07-31 Filed 2015-09-04
10-Q 2015-04-30 Filed 2015-06-05
10-Q 2015-01-31 Filed 2015-03-06
10-K 2014-10-31 Filed 2014-12-19
10-Q 2014-07-31 Filed 2014-09-05
10-Q 2014-04-30 Filed 2014-06-06
10-Q 2014-01-31 Filed 2014-03-07
10-K 2013-10-31 Filed 2013-12-20
10-Q 2013-07-31 Filed 2013-09-06
10-Q 2013-04-30 Filed 2013-06-07
10-Q 2013-01-31 Filed 2013-03-08
10-K 2012-10-31 Filed 2012-12-20
10-Q 2012-07-31 Filed 2012-09-07
10-Q 2012-04-30 Filed 2012-06-08
10-Q 2012-01-31 Filed 2012-03-09
10-K 2011-10-31 Filed 2011-12-16
10-Q 2011-07-31 Filed 2011-09-02
10-Q 2011-04-30 Filed 2011-06-03
10-Q 2011-01-31 Filed 2011-03-04
10-K 2010-10-31 Filed 2010-12-17
10-Q 2010-07-31 Filed 2010-09-03
10-Q 2010-04-30 Filed 2010-06-04
10-Q 2010-01-31 Filed 2010-03-05
8-K 2020-07-01 Officers, Exhibits
8-K 2020-06-04
8-K 2020-04-01
8-K 2020-03-18
8-K 2020-03-05
8-K 2019-12-10
8-K 2019-12-05
8-K 2019-09-27
8-K 2019-08-29
8-K 2019-05-30
8-K 2019-04-17
8-K 2019-03-18
8-K 2019-03-05
8-K 2018-12-12
8-K 2018-12-06
8-K 2018-11-01
8-K 2018-08-30
8-K 2018-06-07
8-K 2018-05-01
8-K 2018-04-23
8-K 2018-04-10
8-K 2018-03-19
8-K 2018-03-08
8-K 2018-03-08
8-K 2018-01-04

COO 10Q Quarterly Report

Part I. Financial Information
Item 1. Unaudited Financial Statements
Note 1. General
Note 2. Leases
Note 3. Acquisitions
Note 4. Inventories
Note 5. Intangible Assets
Note 6. Debt
Note 7. Income Taxes
Note 8. Earnings per Share
Note 9. Share - Based Compensation Plans
Note 10. Stockholders' Equity
Note 11. Fair Value Measurements
Note 12. Employee Benefits
Note 13. Contingencies
Note 14. Business Segment Information
Note 15. Financial Derivatives and Hedging
Item 2. Management's Discussion and Analysis of Financial Condition
Item 3. Quantitative and Qualitative Disclosure About Market Risk
Item 4. Controls and Procedures
Part II - Other Information
Item 1. Legal Proceedings
Item 1A. Risk Factors
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 3. Defaults Upon Senior Securities
Item 4. Mine Safety Disclosures
Item 5. Other Information
Item 6. Exhibits
EX-31.1 coo-ex3112020043010q.htm
EX-31.2 coo-ex3122020043010q.htm
EX-32.1 coo-ex3212020043010q.htm
EX-32.2 coo-ex3222020043010q.htm

Cooper Companies Earnings 2020-04-30

Balance SheetIncome StatementCash Flow
10.08.06.04.02.00.02012201420172020
Assets, Equity
0.70.50.30.2-0.0-0.22012201420172020
Rev, G Profit, Net Income
1.30.80.3-0.3-0.8-1.32012201420172020
Ops, Inv, Fin

Document
false--10-31Q220200000711404164000001340000017000000.0300.10.11200000001200000005320000053300000P5Y000.10.1100000010000000000226.3254.77254.77254.77304.54304.5441000004200000 0000711404 2019-11-01 2020-04-30 0000711404 2020-05-29 0000711404 2019-02-01 2019-04-30 0000711404 2018-11-01 2019-04-30 0000711404 2020-02-01 2020-04-30 0000711404 2019-10-31 0000711404 2020-04-30 0000711404 2020-01-31 0000711404 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-11-01 2019-01-31 0000711404 us-gaap:RetainedEarningsMember 2019-04-30 0000711404 us-gaap:AdditionalPaidInCapitalMember 2020-02-01 2020-04-30 0000711404 us-gaap:RetainedEarningsMember 2019-11-01 2020-01-31 0000711404 us-gaap:AdditionalPaidInCapitalMember 2019-02-01 2019-04-30 0000711404 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-31 0000711404 2019-04-30 0000711404 coo:CommonStockExcludingTreasuryStockParNetValueMember 2018-10-31 0000711404 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-31 0000711404 2019-11-01 2020-01-31 0000711404 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-02-01 2019-04-30 0000711404 us-gaap:TreasuryStockMember 2019-01-31 0000711404 us-gaap:AdditionalPaidInCapitalMember 2018-11-01 2019-01-31 0000711404 us-gaap:AccountingStandardsUpdate201616Member us-gaap:RetainedEarningsMember 2018-11-01 0000711404 coo:CommonStockExcludingTreasuryStockParNetValueMember 2019-01-31 0000711404 coo:CommonStockExcludingTreasuryStockParNetValueMember 2019-04-30 0000711404 us-gaap:TreasuryStockMember 2019-10-31 0000711404 2018-11-01 2019-01-31 0000711404 us-gaap:TreasuryStockMember 2018-10-31 0000711404 us-gaap:TreasuryStockMember 2019-04-30 0000711404 coo:CommonStockExcludingTreasuryStockParNetValueMember 2018-11-01 2019-01-31 0000711404 us-gaap:AdditionalPaidInCapitalMember 2019-11-01 2020-01-31 0000711404 us-gaap:NoncontrollingInterestMember 2018-10-31 0000711404 coo:CommonStockExcludingTreasuryStockParNetValueMember 2020-04-30 0000711404 coo:CommonStockExcludingTreasuryStockParNetValueMember 2020-01-31 0000711404 us-gaap:TreasuryStockMember 2020-01-31 0000711404 us-gaap:RetainedEarningsMember 2018-10-31 0000711404 coo:TreasuryStockParNetValueMember 2020-04-30 0000711404 coo:CommonStockExcludingTreasuryStockParNetValueMember 2020-02-01 2020-04-30 0000711404 us-gaap:RetainedEarningsMember 2020-01-31 0000711404 us-gaap:RetainedEarningsMember 2019-10-31 0000711404 us-gaap:RetainedEarningsMember 2018-11-01 2019-01-31 0000711404 coo:CommonStockExcludingTreasuryStockParNetValueMember 2019-11-01 2020-01-31 0000711404 coo:TreasuryStockParNetValueMember 2019-04-30 0000711404 us-gaap:AdditionalPaidInCapitalMember 2020-04-30 0000711404 us-gaap:RetainedEarningsMember 2020-02-01 2020-04-30 0000711404 us-gaap:AdditionalPaidInCapitalMember 2019-01-31 0000711404 us-gaap:NoncontrollingInterestMember 2019-04-30 0000711404 us-gaap:RetainedEarningsMember 2019-02-01 2019-04-30 0000711404 2019-01-31 0000711404 coo:TreasuryStockParNetValueMember 2019-10-31 0000711404 us-gaap:TreasuryStockMember 2020-02-01 2020-04-30 0000711404 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-31 0000711404 us-gaap:TreasuryStockMember 2018-11-01 2019-01-31 0000711404 us-gaap:AdditionalPaidInCapitalMember 2020-01-31 0000711404 us-gaap:RetainedEarningsMember 2020-04-30 0000711404 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-30 0000711404 coo:TreasuryStockParNetValueMember 2020-01-31 0000711404 us-gaap:AccountingStandardsUpdate201616Member 2018-11-01 0000711404 coo:CommonStockExcludingTreasuryStockParNetValueMember 2019-10-31 0000711404 us-gaap:AdditionalPaidInCapitalMember 2019-10-31 0000711404 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-30 0000711404 us-gaap:AdditionalPaidInCapitalMember 2018-10-31 0000711404 us-gaap:NoncontrollingInterestMember 2020-04-30 0000711404 coo:TreasuryStockParNetValueMember 2019-01-31 0000711404 coo:CommonStockExcludingTreasuryStockParNetValueMember 2019-02-01 2019-04-30 0000711404 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-31 0000711404 us-gaap:TreasuryStockMember 2020-04-30 0000711404 us-gaap:RetainedEarningsMember 2019-01-31 0000711404 us-gaap:NoncontrollingInterestMember 2019-01-31 0000711404 2018-10-31 0000711404 coo:TreasuryStockParNetValueMember 2018-10-31 0000711404 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-11-01 2020-01-31 0000711404 us-gaap:AdditionalPaidInCapitalMember 2019-04-30 0000711404 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-02-01 2020-04-30 0000711404 us-gaap:NoncontrollingInterestMember 2019-10-31 0000711404 us-gaap:NoncontrollingInterestMember 2020-01-31 0000711404 us-gaap:TrademarksMember 2020-04-30 0000711404 us-gaap:OtherIntangibleAssetsMember 2020-04-30 0000711404 us-gaap:OtherIntangibleAssetsMember 2019-10-31 0000711404 coo:Acquisitions2019Member 2020-04-30 0000711404 coo:Acquisitions2018Member 2019-10-31 0000711404 us-gaap:CustomerRelationshipsMember 2020-04-30 0000711404 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-10-31 0000711404 us-gaap:TrademarksMember 2019-10-31 0000711404 us-gaap:CustomerRelationshipsMember 2019-10-31 0000711404 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-04-30 0000711404 coo:CoopersurgicalSegmentMember 2019-10-31 0000711404 coo:CoopervisionSegmentMember 2019-10-31 0000711404 coo:CoopersurgicalSegmentMember 2020-04-30 0000711404 coo:CoopervisionSegmentMember 2020-04-30 0000711404 coo:CoopervisionSegmentMember 2019-11-01 2020-04-30 0000711404 coo:CoopersurgicalSegmentMember 2019-11-01 2020-04-30 0000711404 us-gaap:TrademarksMember 2020-04-30 0000711404 coo:CompositeMember 2019-10-31 0000711404 us-gaap:CustomerRelationshipsMember 2019-10-31 0000711404 coo:CompositeMember 2020-04-30 0000711404 us-gaap:TrademarksMember 2019-11-01 2020-04-30 0000711404 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-11-01 2020-04-30 0000711404 us-gaap:TrademarksMember 2019-10-31 0000711404 us-gaap:CustomerRelationshipsMember 2020-04-30 0000711404 coo:LicenseAndDistributionRightsAndOtherMember 2020-04-30 0000711404 coo:LicenseAndDistributionRightsAndOtherMember 2019-11-01 2020-04-30 0000711404 coo:CompositeMember 2019-11-01 2020-04-30 0000711404 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-10-31 0000711404 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-04-30 0000711404 coo:LicenseAndDistributionRightsAndOtherMember 2019-10-31 0000711404 us-gaap:CustomerRelationshipsMember 2019-11-01 2020-04-30 0000711404 2019-05-01 2019-07-31 0000711404 us-gaap:RevolvingCreditFacilityMember coo:CreditAgreement2020Member us-gaap:LineOfCreditMember 2020-04-30 0000711404 coo:CreditAgreement2020AndTermLoanAgreement2019Member 2020-04-30 0000711404 coo:TermLoanAgreement2019Member coo:TermLoansMember 2020-04-30 0000711404 coo:TermLoanFacility2020Member coo:CreditAgreement2020Member us-gaap:LineOfCreditMember 2020-04-30 0000711404 us-gaap:MediumTermNotesMember 2019-10-31 0000711404 coo:TermLoansMember 2020-04-30 0000711404 coo:OtherDebtMember 2019-10-31 0000711404 coo:OverdraftAndOtherCreditFacilitiesMember 2019-10-31 0000711404 coo:OverdraftAndOtherCreditFacilitiesMember 2020-04-30 0000711404 coo:OtherDebtMember 2020-04-30 0000711404 coo:TermLoansMember 2019-10-31 0000711404 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-10-31 0000711404 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2020-04-30 0000711404 us-gaap:MediumTermNotesMember 2020-04-30 0000711404 coo:RevolvingCreditFacilityAndTermLoanFacility2020Member coo:CreditAgreement2020Member us-gaap:LineOfCreditMember 2020-04-01 2020-04-01 0000711404 coo:TermLoanFacility2016Member coo:CreditAgreement2016Member us-gaap:LineOfCreditMember 2016-03-01 0000711404 coo:RevolvingCreditFacilityAndTermLoanFacility2016Member coo:CreditAgreement2016Member us-gaap:LineOfCreditMember 2020-04-01 2020-04-01 0000711404 coo:TermLoanAgreement2017Member us-gaap:MediumTermNotesMember 2017-11-01 0000711404 coo:TermLoanAgreement2019Member coo:TermLoansMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-09-27 2019-09-27 0000711404 srt:MinimumMember coo:RevolvingCreditFacilityAndTermLoanFacility2020Member coo:CreditAgreement2020Member us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2020-04-01 2020-04-01 0000711404 coo:TermLoanAgreement2017Member us-gaap:MediumTermNotesMember 2020-04-01 2020-04-01 0000711404 srt:MaximumMember coo:RevolvingCreditFacilityAndTermLoanFacility2020Member coo:CreditAgreement2020Member us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2020-04-01 2020-04-01 0000711404 srt:MinimumMember coo:RevolvingCreditFacilityAndTermLoanFacility2020Member coo:CreditAgreement2020Member us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-04-01 2020-04-01 0000711404 us-gaap:RevolvingCreditFacilityMember coo:CreditAgreement2016Member us-gaap:LineOfCreditMember 2016-03-01 0000711404 coo:TermLoanFacility2020Member coo:CreditAgreement2020Member us-gaap:LineOfCreditMember 2020-04-01 0000711404 coo:TermLoanAgreement2019Member coo:TermLoansMember 2020-02-01 2020-04-30 0000711404 coo:RevolvingCreditFacilityAndTermLoanFacility2020Member coo:CreditAgreement2020Member us-gaap:LineOfCreditMember 2020-04-01 0000711404 coo:TermLoanFacility2020Member coo:CreditAgreement2020Member us-gaap:LineOfCreditMember 2020-02-01 2020-04-30 0000711404 us-gaap:RevolvingCreditFacilityMember coo:CreditAgreement2020Member us-gaap:LineOfCreditMember 2020-04-01 2020-04-01 0000711404 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember coo:CreditAgreement2020Member us-gaap:LineOfCreditMember 2020-04-01 2020-04-01 0000711404 coo:TermLoanAgreement2019Member coo:TermLoansMember 2019-11-01 2020-04-30 0000711404 coo:TermLoanAgreement2018Member coo:TermLoansMember 2018-11-01 0000711404 coo:TermLoanAgreement2019Member coo:TermLoansMember 2019-09-27 0000711404 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember coo:CreditAgreement2020Member us-gaap:LineOfCreditMember 2020-04-01 2020-04-01 0000711404 coo:TermLoanAgreement2019Member coo:TermLoansMember us-gaap:BaseRateMember 2019-09-27 2019-09-27 0000711404 coo:TermLoanAgreement2019Member coo:TermLoansMember 2019-09-27 2019-09-27 0000711404 us-gaap:RevolvingCreditFacilityMember coo:CreditAgreement2020Member us-gaap:LineOfCreditMember 2020-04-01 0000711404 coo:TermLoanFacility2020Member coo:CreditAgreement2020Member us-gaap:LineOfCreditMember 2020-04-01 2020-04-01 0000711404 srt:MaximumMember coo:RevolvingCreditFacilityAndTermLoanFacility2020Member coo:CreditAgreement2020Member us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-04-01 2020-04-01 0000711404 coo:TermLoanAgreement2017Member us-gaap:MediumTermNotesMember 2017-11-01 2017-11-01 0000711404 coo:TermLoanFacility2020Member coo:CreditAgreement2020Member us-gaap:LineOfCreditMember 2019-11-01 2020-04-30 0000711404 us-gaap:RestrictedStockUnitsRSUMember 2019-11-01 2020-04-30 0000711404 us-gaap:EmployeeStockOptionMember 2020-02-01 2020-04-30 0000711404 us-gaap:EmployeeStockOptionMember 2018-11-01 2019-04-30 0000711404 us-gaap:RestrictedStockUnitsRSUMember 2019-02-01 2019-04-30 0000711404 us-gaap:EmployeeStockOptionMember 2019-02-01 2019-04-30 0000711404 us-gaap:EmployeeStockOptionMember 2019-11-01 2020-04-30 0000711404 us-gaap:RestrictedStockUnitsRSUMember 2020-02-01 2020-04-30 0000711404 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-11-01 2019-04-30 0000711404 us-gaap:CostOfSalesMember 2018-11-01 2019-04-30 0000711404 us-gaap:CostOfSalesMember 2019-02-01 2019-04-30 0000711404 us-gaap:CostOfSalesMember 2019-11-01 2020-04-30 0000711404 us-gaap:CostOfSalesMember 2020-02-01 2020-04-30 0000711404 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-11-01 2020-04-30 0000711404 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-02-01 2019-04-30 0000711404 us-gaap:ResearchAndDevelopmentExpenseMember 2019-02-01 2019-04-30 0000711404 us-gaap:ResearchAndDevelopmentExpenseMember 2020-02-01 2020-04-30 0000711404 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-02-01 2020-04-30 0000711404 us-gaap:ResearchAndDevelopmentExpenseMember 2018-11-01 2019-04-30 0000711404 us-gaap:ResearchAndDevelopmentExpenseMember 2019-11-01 2020-04-30 0000711404 2017-03-31 0000711404 2011-12-31 0000711404 2018-11-01 2019-10-31 0000711404 2020-02-10 2020-02-10 0000711404 us-gaap:AccumulatedTranslationAdjustmentMember 2019-10-31 0000711404 2017-11-01 2018-10-31 0000711404 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-11-01 2020-04-30 0000711404 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-10-31 0000711404 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-10-31 0000711404 us-gaap:AccumulatedTranslationAdjustmentMember 2018-10-31 0000711404 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-11-01 2018-10-31 0000711404 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2017-11-01 2018-10-31 0000711404 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-10-31 0000711404 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-11-01 2020-04-30 0000711404 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-04-30 0000711404 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-04-30 0000711404 us-gaap:AccumulatedTranslationAdjustmentMember 2020-04-30 0000711404 us-gaap:AccumulatedTranslationAdjustmentMember 2017-11-01 2018-10-31 0000711404 us-gaap:AccumulatedTranslationAdjustmentMember 2019-11-01 2020-04-30 0000711404 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-10-31 0000711404 us-gaap:InterestRateSwapMember 2020-04-06 0000711404 us-gaap:InterestRateSwapMember 2020-04-06 2020-04-06 0000711404 2015-03-01 2015-06-30 0000711404 coo:CoopervisionLitigationMember 2018-07-01 2018-07-31 0000711404 country:US 2019-02-01 2019-04-30 0000711404 country:US 2019-11-01 2020-04-30 0000711404 country:US 2018-11-01 2019-04-30 0000711404 srt:EuropeMember 2019-02-01 2019-04-30 0000711404 srt:EuropeMember 2018-11-01 2019-04-30 0000711404 srt:EuropeMember 2020-02-01 2020-04-30 0000711404 country:US 2020-02-01 2020-04-30 0000711404 coo:RestOfWorldExcludingUnitedStatesAndEuropeMember 2018-11-01 2019-04-30 0000711404 coo:RestOfWorldExcludingUnitedStatesAndEuropeMember 2019-11-01 2020-04-30 0000711404 coo:RestOfWorldExcludingUnitedStatesAndEuropeMember 2020-02-01 2020-04-30 0000711404 srt:EuropeMember 2019-11-01 2020-04-30 0000711404 coo:RestOfWorldExcludingUnitedStatesAndEuropeMember 2019-02-01 2019-04-30 0000711404 coo:MultifocalLensMember coo:CoopervisionSegmentMember 2019-02-01 2019-04-30 0000711404 coo:NonSingleUseSphereAndOtherMember coo:CoopervisionSegmentMember 2019-11-01 2020-04-30 0000711404 coo:SingleUseSphereLensMember coo:CoopervisionSegmentMember 2019-02-01 2019-04-30 0000711404 coo:FertilityMember coo:CoopersurgicalSegmentMember 2018-11-01 2019-04-30 0000711404 coo:CoopersurgicalSegmentMember 2019-02-01 2019-04-30 0000711404 us-gaap:OperatingSegmentsMember coo:CoopervisionSegmentMember 2019-02-01 2019-04-30 0000711404 coo:FertilityMember coo:CoopersurgicalSegmentMember 2019-11-01 2020-04-30 0000711404 coo:MultifocalLensMember coo:CoopervisionSegmentMember 2020-02-01 2020-04-30 0000711404 coo:CoopersurgicalSegmentMember 2020-02-01 2020-04-30 0000711404 coo:CoopervisionSegmentMember 2020-02-01 2020-04-30 0000711404 us-gaap:OperatingSegmentsMember coo:CoopersurgicalSegmentMember 2018-11-01 2019-04-30 0000711404 us-gaap:OperatingSegmentsMember coo:CoopervisionSegmentMember 2018-11-01 2019-04-30 0000711404 us-gaap:CorporateNonSegmentMember 2018-11-01 2019-04-30 0000711404 coo:CoopervisionSegmentMember 2019-02-01 2019-04-30 0000711404 coo:OfficeAndSurgicalProductsMember coo:CoopersurgicalSegmentMember 2019-02-01 2019-04-30 0000711404 coo:CoopervisionSegmentMember 2018-11-01 2019-04-30 0000711404 coo:ToricLensMember coo:CoopervisionSegmentMember 2020-02-01 2020-04-30 0000711404 us-gaap:CorporateNonSegmentMember 2019-11-01 2020-04-30 0000711404 us-gaap:OperatingSegmentsMember coo:CoopersurgicalSegmentMember 2019-02-01 2019-04-30 0000711404 coo:SingleUseSphereLensMember coo:CoopervisionSegmentMember 2019-11-01 2020-04-30 0000711404 coo:NonSingleUseSphereAndOtherMember coo:CoopervisionSegmentMember 2020-02-01 2020-04-30 0000711404 us-gaap:OperatingSegmentsMember coo:CoopersurgicalSegmentMember 2020-02-01 2020-04-30 0000711404 coo:OfficeAndSurgicalProductsMember coo:CoopersurgicalSegmentMember 2019-11-01 2020-04-30 0000711404 coo:CoopersurgicalSegmentMember 2018-11-01 2019-04-30 0000711404 coo:SingleUseSphereLensMember coo:CoopervisionSegmentMember 2020-02-01 2020-04-30 0000711404 us-gaap:OperatingSegmentsMember coo:CoopervisionSegmentMember 2019-11-01 2020-04-30 0000711404 coo:ToricLensMember coo:CoopervisionSegmentMember 2019-11-01 2020-04-30 0000711404 us-gaap:CorporateNonSegmentMember 2020-02-01 2020-04-30 0000711404 coo:NonSingleUseSphereAndOtherMember coo:CoopervisionSegmentMember 2018-11-01 2019-04-30 0000711404 us-gaap:OperatingSegmentsMember coo:CoopervisionSegmentMember 2020-02-01 2020-04-30 0000711404 coo:NonSingleUseSphereAndOtherMember coo:CoopervisionSegmentMember 2019-02-01 2019-04-30 0000711404 coo:ToricLensMember coo:CoopervisionSegmentMember 2018-11-01 2019-04-30 0000711404 coo:OfficeAndSurgicalProductsMember coo:CoopersurgicalSegmentMember 2020-02-01 2020-04-30 0000711404 coo:MultifocalLensMember coo:CoopervisionSegmentMember 2019-11-01 2020-04-30 0000711404 coo:ToricLensMember coo:CoopervisionSegmentMember 2019-02-01 2019-04-30 0000711404 coo:FertilityMember coo:CoopersurgicalSegmentMember 2020-02-01 2020-04-30 0000711404 us-gaap:OperatingSegmentsMember coo:CoopersurgicalSegmentMember 2019-11-01 2020-04-30 0000711404 coo:FertilityMember coo:CoopersurgicalSegmentMember 2019-02-01 2019-04-30 0000711404 coo:SingleUseSphereLensMember coo:CoopervisionSegmentMember 2018-11-01 2019-04-30 0000711404 coo:MultifocalLensMember coo:CoopervisionSegmentMember 2018-11-01 2019-04-30 0000711404 coo:OfficeAndSurgicalProductsMember coo:CoopersurgicalSegmentMember 2018-11-01 2019-04-30 0000711404 us-gaap:CorporateNonSegmentMember 2019-02-01 2019-04-30 0000711404 us-gaap:CorporateNonSegmentMember 2020-04-30 0000711404 us-gaap:CorporateNonSegmentMember 2019-10-31 0000711404 us-gaap:OperatingSegmentsMember coo:CoopervisionSegmentMember 2020-04-30 0000711404 us-gaap:OperatingSegmentsMember coo:CoopervisionSegmentMember 2019-10-31 0000711404 us-gaap:OperatingSegmentsMember coo:CoopersurgicalSegmentMember 2020-04-30 0000711404 us-gaap:OperatingSegmentsMember coo:CoopersurgicalSegmentMember 2019-10-31 0000711404 coo:RestOfWorldExcludingUnitedStatesAndEuropeMember 2019-10-31 0000711404 country:US 2020-04-30 0000711404 srt:EuropeMember 2019-10-31 0000711404 country:US 2019-10-31 0000711404 srt:EuropeMember 2020-04-30 0000711404 coo:RestOfWorldExcludingUnitedStatesAndEuropeMember 2020-04-30 0000711404 us-gaap:InterestRateSwapMember 2020-04-30 0000711404 us-gaap:InterestRateSwapMember 2019-11-01 2020-04-30 0000711404 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-04-30 0000711404 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-04-30 0000711404 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-04-30 0000711404 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-04-30 0000711404 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-04-30 0000711404 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-04-30 iso4217:USD xbrli:shares coo:interest_rate_swap_contract iso4217:USD xbrli:shares coo:action xbrli:pure coo:segment
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________
FORM 10-Q
_____________________________________________________________
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended April 30, 2020
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from              to             
Commission File Number 1-8597
_____________________________________________________________
The Cooper Companies, Inc.
(Exact name of registrant as specified in its charter)
_____________________________________________________________
Delaware
94-2657368
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
6101 Bollinger Canyon Road, Suite 500,
San Ramon, California 94583
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (925460-3600
_____________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol
 
Name of each exchange on which registered
Common Stock, $.10 par value
 
COO
 
The New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 
Accelerated filer
Non-accelerated filer
 
Smaller reporting company
Emerging growth company
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.):    Yes      No  
On May 29, 2020, 53,333,091 shares of Common Stock, $.10 par value, were outstanding.




 
 
 


INDEX
 
 
 
Page No.
PART I.
 
 
 
 
Item 1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Item 2.
 
 
 
Item 3.
 
 
 
Item 4.
 
 
 
PART II.
 
 
 
 
Item 1.
 
 
 
Item 1A.
 
 
 
Item 2.
 
 
 
Item 3.
 
 
 
Item 4.
 
 
 
Item 5.
 
 
 
Item 6.
 
 

2



 
 
 

PART I. FINANCIAL INFORMATION
Item 1. Unaudited Financial Statements
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Statements of Income and Comprehensive Income (Loss)
Periods Ended April 30,
(In millions, except for earnings per share)
(Unaudited)
 
Three Months
 
Six Months
  
2020
 
2019
 
2020
 
2019
Net sales
$
524.9

 
$
654.3

 
$
1,171.1

 
$
1,282.4

Cost of sales
201.4

 
221.7

 
421.1

 
431.3

Gross profit
323.5

 
432.6

 
750.0

 
851.1

Selling, general and administrative expense
237.2

 
246.8

 
495.5

 
496.8

Research and development expense
23.8

 
21.0

 
46.0

 
42.0

Amortization of intangibles
33.9

 
36.9

 
68.8

 
73.5

Gain on sale of an intangible

 
(19.0
)
 

 
(19.0
)
Operating income
28.6

 
146.9

 
139.7

 
257.8

Interest expense
12.8


18.5


24.4


36.6

Other expense (Income), net
6.8


0.3


8.9


(0.7
)
Income before income taxes
9.0

 
128.1

 
106.4

 
221.9

(Benefit) Provision for income taxes (Note 7)
(2.5
)
 
5.7

 
4.4

 
(3.6
)
Net income
$
11.5

 
$
122.4

 
$
102.0

 
$
225.5

Earnings per share (Note 8):
 
 
 
 
 
 
 
Basic
$
0.23

 
$
2.48

 
$
2.07

 
$
4.57

Diluted
$
0.23

 
$
2.45

 
$
2.05

 
$
4.52

Number of shares used to compute earnings per share:

 

 

 

Basic
49.2

 
49.4

 
49.2

 
49.3

Diluted
49.6

 
50.0

 
49.7

 
49.9

Other comprehensive income, net of tax:
 
 
 
 
 
 
 
Cash flow hedge
$
(13.5
)
 

 
$
(13.5
)
 

Foreign currency translation adjustment
(68.9
)
 
(18.6
)
 
(52.2
)
 
14.1

Comprehensive (loss) income
$
(70.9
)
 
$
103.8

 
$
36.3

 
$
239.6


The accompanying notes are an integral part of these Consolidated Condensed Financial Statements.


3



 
 
 


THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Consolidated Condensed Balance Sheets
(In millions, unaudited)
 
April 30, 2020
 
October 31, 2019
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
79.8

 
$
89.0

Trade accounts receivable, net of allowance for doubtful accounts of $13.4 at April 30, 2020 and $16.4 at October 31, 2019
368.8

 
435.3

Inventories (Note 4)
568.2

 
506.9

Prepaid expense and other current assets
149.4

 
132.2

Total current assets
1,166.2

 
1,163.4

Property, plant and equipment, at cost
2,309.5

 
2,193.9

Less: accumulated depreciation and amortization
1,113.4

 
1,061.8

 
1,196.1

 
1,132.1

Operating lease right-of-use assets (Note 2)
255.5

 

Goodwill (Note 5)
2,400.0

 
2,428.9

Other intangibles, net (Note 5)
1,337.7

 
1,405.3

Deferred tax assets
77.0

 
78.0

Other assets
77.5

 
66.8

Total assets
$
6,510.0

 
$
6,274.5

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Short-term debt (Note 6)
$
554.5

 
$
563.7

Accounts payable
128.7

 
150.1

Employee compensation and benefits
86.3

 
104.7

Operating lease liabilities
31.5

 

Other current liabilities
224.3

 
292.1

Total current liabilities
1,025.3

 
1,110.6

Long-term debt (Note 6)
1,344.8

 
1,262.6

Deferred tax liabilities
26.8

 
28.0

Long-term tax payable
158.9

 
124.8

Operating lease liabilities
232.7

 

Accrued pension liability and other
94.0

 
119.9

Total liabilities
$
2,882.5

 
$
2,645.9

Contingencies (Note 13)

 

Stockholders’ equity:
 
 
 
Preferred stock, 10 cents par value, shares authorized: 1.0; zero shares issued or outstanding

 

Common stock, 10 cents par value, shares authorized: 120.0; issued 53.3 at April 30, 2020 and 53.2 at October 31, 2019
5.3

 
5.3

Additional paid-in capital
1,626.5

 
1,615.0

Accumulated other comprehensive loss
(512.8
)
 
(447.1
)
Retained earnings
3,126.9

 
3,026.4

Treasury stock at cost: 4.2 shares at April 30, 2020 and 4.1 shares at October 31, 2019
(618.6
)
 
(571.2
)
Total Cooper stockholders’ equity
3,627.3

 
3,628.4

Noncontrolling interests
0.2

 
0.2

Stockholders’ equity (Note 10)
3,627.5

 
3,628.6

Total liabilities and stockholders’ equity
$
6,510.0

 
$
6,274.5


The accompanying notes are an integral part of these Consolidated Condensed Financial Statements.

4

THE COOPER COMPANIES, INC. AND SUBSIDIARIES


Consolidated Condensed Statements of Stockholders' Equity
(In millions, unaudited)
 
Common Shares
 
Treasury Stock
 
Additional Paid-In Capital
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Retained Earnings
 
Treasury Stock
 
Noncontrolling Interests
 
Total
Stockholders'
Equity
(In millions)
Shares
 
Amount
 
Shares
 
Amount
 
 
 
 
 
 
Balance at November 1, 2018
49.2

 
$
5.0

 
3.6

 
$
0.3

 
$
1,572.1

 
$
(430.7
)
 
$
2,576.0

 
$
(415.1
)
 
$
0.2

 
$
3,307.8

Net income

 

 

 

 

 

 
103.2

 

 

 
103.2

Other comprehensive income, net of tax

 

 

 

 

 
32.7

 

 

 

 
32.7

Issuance of common stock for stock plans, net
0.1

 

 

 

 
(9.0
)
 

 

 

 

 
(9.0
)
Treasury stock repurchase

 

 

 

 

 

 

 
(6.1
)
 

 
(6.1
)
Dividends on common stock ($0.03 per share)

 

 

 

 

 

 
(1.5
)
 

 

 
(1.5
)
Share-based compensation expense

 

 

 

 
11.7

 

 

 

 

 
11.7

ASU 2016-16 adoption

 

 

 

 

 

 
(13.3
)
 

 

 
(13.3
)
Balance at January 31, 2019
49.3

 
$
5.0

 
3.6

 
$
0.3

 
$
1,574.8

 
$
(398.0
)
 
$
2,664.4

 
$
(421.2
)
 
$
0.2

 
$
3,425.5

Net income

 

 

 

 

 

 
122.4

 

 

 
122.4

Other comprehensive loss, net of tax

 

 

 

 

 
(18.6
)
 

 

 

 
(18.6
)
Issuance of common stock for stock plans, net
0.2

 

 

 

 
4.5

 

 

 

 

 
4.5

Share-based compensation expense

 

 

 

 
8.4

 

 

 

 

 
8.4

Balance at April 30, 2019
49.5

 
$
5.0

 
3.6

 
$
0.3

 
$
1,587.7

 
$
(416.6
)
 
$
2,786.8

 
$
(421.2
)
 
$
0.2

 
$
3,542.2

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at November 1, 2019
49.1

 
$
4.9

 
4.1

 
$
0.4

 
$
1,615.0

 
$
(447.1
)
 
$
3,026.4

 
$
(571.2
)
 
$
0.2

 
$
3,628.6

Net income

 

 

 

 

 

 
90.5

 

 

 
90.5

Other comprehensive income, net of tax

 

 

 

 

 
16.7

 

 

 

 
16.7

Issuance of common stock for stock plans, net
0.1

 

 

 

 
(13.2
)
 

 

 

 

 
(13.1
)
Dividends on common stock ($0.03 per share)

 

 

 

 

 

 
(1.5
)
 

 

 
(1.5
)
Share-based compensation expense

 

 

 

 
9.7

 

 

 

 

 
9.7

Balance at January 31, 2020
49.2

 
$
4.9

 
4.1

 
$
0.4

 
$
1,611.6

 
$
(430.4
)
 
$
3,115.4

 
$
(571.2
)
 
$
0.2

 
$
3,730.9

Net income

 

 

 

 

 

 
11.5

 

 

 
11.5

Other comprehensive income, net of tax

 

 

 

 

 
(82.4
)
 

 

 

 
(82.4
)
Issuance of common stock for stock plans, net
0.1

 

 

 

 
5.0

 

 

 

 

 
5.0

Treasury stock repurchase
(0.2
)
 

 
0.2

 

 

 

 

 
(47.8
)
 

 
(47.8
)
Issuance of common stock for employee stock purchase plan

 

 

 

 
0.6

 

 

 
0.4

 

 
1.0

Share-based compensation expense

 

 

 

 
9.3

 

 

 

 

 
9.3

Balance at April 30, 2020
49.1

 
$
4.9

 
4.3

 
$
0.4

 
$
1,626.5

 
$
(512.8
)
 
$
3,126.9

 
$
(618.6
)
 
$
0.2

 
$
3,627.5


The accompanying notes are an integral part of these Consolidated Condensed Financial Statements.

5



 
 
 

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Consolidated Condensed Statements of Cash Flows
Six Months Ended April 30,
(In millions, unaudited)
 
2020
 
2019
Cash flows from operating activities:
 
 
 
Net income
$
102.0

 
$
225.5

Depreciation and amortization
139.4

 
139.5

Gain on sale of an intangible

 
(19.0
)
Decrease in operating capital
(119.8
)
 
(19.7
)
Other non-cash items
33.9

 
(9.7
)
Net cash provided by operating activities
155.5

 
316.6

Cash flows from investing activities:
 
 
 
Purchases of property, plant and equipment
(158.3
)
 
(131.9
)
Acquisitions of businesses and assets, net of cash acquired, and other
(11.2
)
 
(50.8
)
Net cash used in investing activities
(169.5
)
 
(182.7
)
Cash flows from financing activities:
 
 
 
Proceeds from long-term debt
1,862.0

 
424.8

Repayments of long-term debt
(1,781.3
)
 
(938.8
)
Net (repayments) proceeds from short-term debt
(10.0
)
 
417.4

Net payments related to share-based compensation awards
(8.4
)
 
(4.3
)
Dividends on common stock
(1.5
)
 
(1.5
)
Repurchase of common stock
(47.8
)
 
(6.1
)
Issuance of common stock for employee stock purchase plan
0.9

 

Debt issuance costs
(5.5
)
 
(0.2
)
Net cash provided by (used in) financing activities
8.4

 
(108.7
)
Effect of exchange rate changes on cash, cash equivalents and restricted cash
(3.1
)
 
(0.5
)
Net (decrease) increase in cash, cash equivalents and restricted cash
(8.7
)
 
24.7

Cash, cash equivalents and restricted cash at beginning of period
89.5

 
80.2

Cash, cash equivalents and restricted cash at end of period
$
80.8

 
$
104.9

Reconciliation of cash flow information:
 
 
 
Cash and cash equivalents
$
79.8

 
$
104.6

Restricted cash included in other current assets
1.0

 
0.3

Total cash, cash equivalents and restricted cash
$
80.8

 
$
104.9


The accompanying notes are an integral part of these Consolidated Condensed Financial Statements.



6

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

Note 1. General

The accompanying Consolidated Condensed Financial Statements of the Cooper Companies, Inc. and its subsidiaries (the Company) have been prepared in accordance with U.S. GAAP for interim financial information and with the requirements of Regulation S-X, Rule 10-01 for financial statements required to be filed as a part of this Quarterly Report on Form 10-Q. Unless the context requires otherwise, terms "the Company", "we", "us", and "our" are used to refer collectively to the Cooper Companies, Inc. and its subsidiaries.

The accompanying Consolidated Condensed Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of the Cooper Companies, Inc. and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2019. The Consolidated Condensed Financial Statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. Readers should not assume that the results reported here either indicate or guarantee future performance.
Accounting Policies

There have been no material changes to our significant accounting policies described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2019, except as it relates to the adoption of Accounting Standards Update (ASU) 2016-02, Leases (Topic 842), which is described below.
Leases
We consider an arrangement a lease if the arrangement transfers the right to control the use of an identified asset in exchange for consideration. We have operating leases, but do not have material financing leases. Lease right-of-use assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make payments arising from the lease agreement. These assets and liabilities are recognized at the commencement of the lease based upon the present value of the future minimum lease payments over the lease term.
The lease term reflects the noncancelable period of the lease together with periods covered by an option to extend or terminate the lease when management is reasonably certain that it will exercise such option. Changes in the lease term assumption could impact the right-of-use assets and lease liabilities recognized on the balance sheet. As our leases typically do not contain a readily determinable implicit rate, we determine the present value of the lease liability using our incremental borrowing rate at the lease commencement date based on the lease term on a collateralized basis.

Estimates

The World Health Organization has categorized the Coronavirus disease 2019 ("COVID-19") as a pandemic. The COVID-19 pandemic has caused a severe global health crisis, along with economic and societal disruptions and uncertainties, which have negatively impacted business and healthcare activity globally. As a result of healthcare systems responding to the demands of managing the pandemic, governments around the world imposing measures designed to reduce the transmission of the COVID-19 virus, and individuals responding to the concerns of contracting the COVID-19 virus, many of our optical retailers, hospital, medical office and fertility clinic customers have closed their facilities, restricted access, or delayed or cancelled patient visits, exams and elective medical procedures. This has had, and we believe will continue to have, an adverse effect on our sales, operating results and cash flows, although the extent of which is uncertain.
The preparation of Consolidated Condensed Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates particularly as it relates to estimates reliant on forecasts and other assumptions reasonably available to the Company and the uncertain future impacts of the COVID-19 pandemic and related economic disruptions. The extent to which the COVID-19 pandemic and related economic disruptions impact our business and financial results will depend on future developments including, but not limited to, the continued spread, duration and severity of the COVID-19 pandemic; the occurrence, spread, duration and severity of any subsequent wave or waves of outbreaks after the initial outbreak has subsided; the actions taken by the U.S. and foreign governments to contain the COVID-19 pandemic, address its impact or respond to the reduction

7

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

in global and local economic activity; the occurrence, duration and severity of a global, regional or national recession, depression or other sustained adverse market event; the impact of the developments described above on our customers and suppliers; and how quickly and to what extent normal economic and operating conditions can resume. The accounting matters assessed included, but were not limited to:
allowance for doubtful accounts and credit losses
carrying value of inventory
the carrying value of the goodwill and other long-lived assets.
There was not a material impact to the above estimates in the Company’s Consolidated Condensed Financial Statements for the three and six months ended April 30, 2020. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material changes to the estimates and material impacts to the Company’s Consolidated Condensed Financial Statements in future reporting periods.
Accounting Pronouncements Recently Adopted

In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (ROU) asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases and ASU 2018-11, Leases Topic 842 Target improvements, which provides an additional (and optional) transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. In March 2019, the FASB issued ASU 2019-01, Leases (Topic 842) Codification Improvements, which further clarifies the determination of fair value of the underlying asset by lessors that are not manufacturers or dealers and modifies transition disclosure requirements for changes in accounting principles and other technical updates.

We adopted this standard using the optional transition method and recorded an adjustment to the Consolidated Condensed Balance Sheet on November 1, 2019. We have implemented changes to certain business processes, systems and internal controls to support adoption of the new standard and the related disclosure requirements, including the implementation of a third-party leasing software solution. We elected the package of transition expedients, which allows us to keep our existing lease classifications and not reassess whether any existing contracts as of the date of adoption are leases or contain leases and not reassess initial direct costs. In addition, we elected the practical expedients to combine lease and non-lease components for our leases, and for leases with an initial term of 12 months or less to recognize the associated lease payments in the Consolidated Statements of Income and Comprehensive Income on a straight-line basis over the lease term.

As of April 30, 2020, the aggregate balances of lease right-of-use assets and lease liabilities were $255.5 million and $264.2 million, respectively. The standard did not affect our Consolidated Statements of Income and Comprehensive Income or Consolidated Condensed Statements of Cash Flows. We will continue to disclose comparative reporting periods prior to November 1, 2019 under the previous accounting guidance, ASC 840 Leases.

8

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

Accounting Pronouncements Issued Not Yet Adopted

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” and subsequent amendments to the initial guidance: ASU 2018-19 “Codification Improvements to Topic 326, Financial Instruments-Credit Losses”, ASU 2019-04 “Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments”, ASU 2019-05 “Financial Instruments-Credit Losses”, ASU 2019-11 “Codification Improvements to Topic 326, Financial Instruments - Credit Losses” (collectively, “Topic 326”), ASU 2020-02 Financial Instruments—Credit Losses (Topic 326) and Leases (Topic 842) and ASU 2020-03 Codification Improvements to Financial Instruments. Topic 326 requires measurement and recognition of expected credit losses for financial assets held. Topic 326 is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019, which means it will be effective for our fiscal year beginning November 01, 2020. Early adoption is permitted. We are currently evaluating the impact of Topic 326 on our Consolidated Condensed Financial Statements.

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808), Clarifying the Interaction between Topic 808 and Topic 606. This guidance amended Topic 808 and Topic 606 to clarify that transactions in a collaborative arrangement should be accounted for under Topic 606 when the counterparty is a customer for a distinct good or service (i.e., unit of account). The amendments preclude an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, which means it will be effective for our fiscal year beginning November 1, 2020. Early adoption is permitted. The adoption of this guidance will not have a material impact on our Consolidated Condensed Financial Statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This guidance removes certain exceptions to the general principles in Topic 740 and enhances and simplifies various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating the impact of ASU 2019-12 on our Consolidated Condensed Financial Statements, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2021.

In January 2020, the FASB issued ASU 2020-01 Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) - Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. This guidance addresses accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating the impact of ASU 2020-01 on our Consolidated Condensed Financial Statements, which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2021.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This guidance provides optional expedients and exceptions for applying generally accepted accounting principles (GAAP) to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance is effective for all entities as of March 12, 2020 through December 31, 2022. We are currently evaluating the impact of ASU 2020-04 on our Consolidated Condensed Financial Statements.
No other recently issued accounting pronouncements had or are expected to have a material impact on our Consolidated Condensed Financial Statements. 

9

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

Note 2. Leases

The Company primarily has operating leases for office, manufacturing and warehouse space, vehicles, and office equipment. Our leases expire on various dates between 2020 and 2045, some of which could include options to extend the lease.

Lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As these leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease's commencement date in determining the present value of lease payments. We consider information including, but not limited to, the lease term, our credit rating and interest rates of similar debt instruments with comparable credit ratings and security interests. The lease right-of-use assets are increased by any lease prepayments made and reduced by any lease incentives such as tenant improvement allowances. Options to extend the lease term are included in the lease term when it is reasonably certain that we will exercise the extension option.

The Company’s operating leases typically include non-lease components such as common-area maintenance costs. We have elected to include non-lease components with lease payments for the purpose of calculating lease right-of-use assets and liabilities, to the extent that they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments.

Leases with a term of one year or less are not recognized on our Consolidated Condensed Balance Sheet, while the associated lease payments are recorded in the Consolidated Statements of Income and Comprehensive Income on a straight-line basis over the lease term.

Commitments under finance lease arrangements of $1.9 million as of April 30, 2020 are not significant and are not included in the disclosure tables below.
The following table presents information about leases on the Consolidated Condensed Balance Sheet:
(In millions)
April 30, 2020
Operating Leases
 
Operating lease right-of-use assets
$
255.5

 
 
Operating lease liabilities, current
31.5

Operating lease liabilities, non-current
232.7

Total operating lease liabilities
$
264.2

 
 
Weighted average remaining lease term (in years)

11.6

Weighted average discount rate
3
%

The following table presents information about lease expense in our Consolidated Statements of Income and Comprehensive Income:
Periods Ended April 30,
Three Months
 
Six Months
(In millions)
2020
 
2020
Operating lease expense
$
9.7

 
$
19.6

Short-term lease expense
1.5

 
2.6

Variable lease expense
0.4

 
0.8



10

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

The following table presents supplemental cash flow information about the Company’s leases:
Periods Ended April 30,
Three Months
 
Six Months
(In millions)
2020
 
2020
Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
   Operating cash flows from operating leases
$
9.7

 
$
19.6


Maturity of Lease Liabilities
The minimum rental payments required under operating leases that have initial or remaining noncancelable lease terms in excess of one year as of April 30, 2020 are:
(In millions)
 
Remainder of 2020
$
19.1

2021
36.5

2022
32.6

2023
29.2

2024
27.1

2025 and thereafter
173.9

Total lease payments
318.4

Less: interest
54.2

Present value of lease liabilities
$
264.2



As previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2019, and under previous lease accounting standard ASC 840, Leases, the aggregate future noncancelable minimum rental payments on its operating leases, as of October 31, 2019, were as follows:
(In millions)
 
2020
$
38.5

2021
34.9

2022
31.2

2023
28.0

2024
26.5

2025 and thereafter
173.6

Total future minimum lease payments
$
332.7





11

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

Note 3. Acquisitions
The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during fiscal 2020 and 2019:
(In millions)
April 30, 2020
 
October 31, 2019
Customer relationships
$
6.5

 
$
7.5

Technology

 
12.3

Trademarks

 
10.2

Other

 
0.1

Total identifiable intangible assets
$
6.5

 
$
30.1

Goodwill
1.9

 
29.8

Net tangible assets
0.8

 
7.3

Total purchase price
$
9.2

 
$
67.2


All acquisitions were funded by cash generated from operations or facility borrowings.
For business acquisitions, we recorded tangible and intangible assets acquired and liabilities assumed at their fair values as of the applicable date of acquisition. For asset acquisitions, we recorded tangible and intangible assets acquired and liabilities assumed at their estimated and relative fair values as of the applicable date of acquisition.

We believe these acquisitions strengthen CooperSurgical's and CooperVision's businesses through the addition of new distributors or complementary products and services.

The pro forma results of operations have not been presented because the effect of the business combinations described below were not material to our consolidated results of operations.
Fiscal Year 2020

On December 13, 2019, CooperSurgical completed the acquisition of a privately-held distributor of in vitro fertilization (IVF) medical devices and systems. The purchase price allocation is preliminary and we are in the process of finalizing information and the corresponding impact on goodwill.
Fiscal Year 2019

On December 28, 2018, CooperVision completed the acquisition of Blanchard Contact Lenses. Blanchard is a privately-held scleral lens company, which expands CooperVision's specialty and scleral lens portfolio.

On December 31, 2018, CooperSurgical completed the acquisition of Incisive Surgical Inc., a privately-held U.S. medical device company that develops mechanical surgical solutions for skin closure.

Note 4. Inventories
(In millions)
April 30, 2020
 
October 31, 2019
Raw materials
$
141.1

 
$
131.4

Work-in-process
13.0
 
13.3
Finished goods
414.1
 
362.2
Total inventories
$
568.2

 
$
506.9


Inventories are stated at the lower of cost and net realizable value. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis.

12

THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)

Note 5. Intangible Assets

Goodwill
(In millions)
CooperVision
 
CooperSurgical
 
Total
Balance at October 31, 2019
1,765.4

 
663.5

 
2,428.9

Current period additions

 
1.9

 
1.9

Foreign currency translation adjustment
(27.2
)
 
(3.6
)
 
(30.8
)
Balance at April 30, 2020
$
1,738.2

 
$
661.8

 
$
2,400.0



The Company evaluates goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. The Company accounts for goodwill, evaluates and tests goodwill balances for impairment in accordance with related accounting standards. The Company performed an annual impairment assessment in third quarter of fiscal 2019, and its analysis indicated that there was no impairment of goodwill in reporting units.
Other Intangible Assets
 
April 30, 2020
 
October 31, 2019
 
 
(In millions)
Gross Carrying
Amount
 
Accumulated
Amortization
 
Gross Carrying
Amount
 
Accumulated
Amortization
 
Weighted Average Amortization Period (in years)
Intangible assets with definite lives:
 
 
 
 
 
 
 
 
 
Trademarks
$
147.7

 
$
32.3

 
$
148.5

 
$
27.3

 
14
Composite intangible asset
1,061.9

 
177.0

 
1,061.9

 
141.6

 
15
Technology
399.3

 
236.2

 
399.9

 
221.2

 
11
Customer relationships
357.7

 
203.5

 
357.6

 
194.0

 
13
License and distribution rights and other
27.9

 
16.7

 
27.9

 
15.3

 
11
 
1,994.5

 
$
665.7

 
1,995.8

 
$
599.4

 
14
Less: accumulated amortization and translation
665.7

 
 
 
599.4

 
 
 
 
Intangible assets with definite lives, net
1,328.8

 
 
 
1,396.4

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intangible assets with indefinite lives, net (1)
8.9